UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014251
Receipt number R000016568
Scientific Title Phase II trial of conversion surgery for unresectable gastric cancer
Date of disclosure of the study information 2014/06/12
Last modified on 2023/06/30 15:12:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II trial of conversion surgery for unresectable gastric cancer

Acronym

Conversion surgery for gastric cancer

Scientific Title

Phase II trial of conversion surgery for unresectable gastric cancer

Scientific Title:Acronym

Conversion surgery for gastric cancer

Region

Japan


Condition

Condition

Gastric cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of efficacy and safety of conversion surgery for unresectable gastric cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

3 year survival rate

Key secondary outcomes

5 year survival rate, curative resection rate of conversion surgery, 3 year survival rate from conversion surgery, pathological response, adverse event


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

gastrectomy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Histologically confirmed gastric cancer
2) Clinically diagnosed unresectable gastric cancer patients performed chemotherapy
3) No history of gastrectomy
4) Clinically diagnosed resectable after chemotherapy
5) Age between 20 and 80 at registration
6) Performance Status(ECOG) 0 or 1
7) Fair oral intake
8) Adequate organ functions
9) Written informed consent from patient

Key exclusion criteria

1) Synchronous other cancer
2) Female with present pregnancy or breast-feeding, or contemplating pregnancy
3) Mental disorders which may affect ability or willingness to provide informed consent of the study
4) Continuous systemic steroid therapy
5) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema
6) Active bacterial or fungal infection
7) Past history of myocardial infarction or unstable angina within 6 months
8) Uncontrollable hypertension

Target sample size

25


Research contact person

Name of lead principal investigator

1st name Seiji
Middle name
Last name Ito

Organization

Aichi Cancer Center Hospital

Division name

Department of Gastroenterological Surgery

Zip code

464-8681

Address

1-1 Kanokoden Chikuda-ku Nagoya Japan

TEL

0527626111

Email

seito@aichi-cc.jp


Public contact

Name of contact person

1st name Seij
Middle name
Last name Ito

Organization

Aichi Cancer Center Hospital

Division name

Department of Gastroenterological Surgery

Zip code

464-8681

Address

1-1 Kanokoden Chikuda-ku Nagoya Japan

TEL

0527626111

Homepage URL


Email

seito@aichi-cc.jp


Sponsor or person

Institute

Chubu Clinical Oncology Group (CCOG)

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Aichi Cancer Center Institutional Review Board

Address

1-1 Kanokoden Chikuda-ku Nagoya Japan

Tel

052-762-6111

Email

koutaku_kitano@aichi-cc.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 06 Month 12 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

30

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2013 Year 11 Month 11 Day

Date of IRB

2013 Year 12 Month 13 Day

Anticipated trial start date

2014 Year 03 Month 01 Day

Last follow-up date

2024 Year 08 Month 31 Day

Date of closure to data entry

2024 Year 09 Month 30 Day

Date trial data considered complete

2024 Year 09 Month 30 Day

Date analysis concluded

2024 Year 12 Month 31 Day


Other

Other related information



Management information

Registered date

2014 Year 06 Month 12 Day

Last modified on

2023 Year 06 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016568


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name